Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-04-30T18:33:49.472Z Has data issue: false hasContentIssue false

22 - Rheumatoid Arthritis/SLE

from PART V - INFLAMMATORY DISEASES/HISTOLOGY

Published online by Cambridge University Press:  05 April 2014

Karim Raza
Affiliation:
University of Birmingham
Caroline Gordon
Affiliation:
University of Birmingham
Charles N. Serhan
Affiliation:
Harvard Medical School
Peter A. Ward
Affiliation:
University of Michigan, Ann Arbor
Derek W. Gilroy
Affiliation:
University College London
Get access

Summary

RHEUMATOID ARTHRITIS

Rheumatoid Arthritis: Clinical Case

A 60-year-old man presented with a 4-week history of a gradually worsening ankle pain and swelling. He gave no history of morning stiffness, or symptoms in any other joints. There was no preceding history of infection (including of the gastrointestinal or genitourinary tract) and no history of previous inflammatory disease (including the skin and eye). There was a family history of rheumatoid arthritis with his daughter having been diagnosed with this condition at the age of 30. He smoked 10 cigarettes per day and drank 6 units of alcohol per week. He had been treated with diclofenac by his primary care physician but had derived little benefit from this.

On examination, he had tenderness with clinically apparent synovial swelling at the left ankle (Figure 22.1A). The remainder of the physical examination was normal.

The differential diagnosis of an inflammatory monoarthritis includes septic arthritis and crystal arthritis and to exclude these diagnoses the patient underwent an ultrasound guided joint aspiration (Figure 22.2). No organisms were identified on synovial fluid microscopy or culture and no crystals were seen on polarized light microscopy. Further investigations revealed the following: ESR 16 mm/h, CRP 17 mg/L (normal < 5 mg/L), rheumatoid factor 72 IU/mL (positive > 20 IU/ mL), anti-CCP antibody 81 U/mL (positive > 10 U/mL), chest radiograph normal.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Arnett, F.C., Edworthy, S.M., Bloch, D.A., et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324.CrossRefGoogle ScholarPubMed
2. Fransen, J., and van Riel, P.L. 2005. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23:S93–S99.Google ScholarPubMed
3. Tunn, E.J., and Bacon, P.A. 1993. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic [see comments]. Br J Rheumatol 32:97–103.CrossRefGoogle Scholar
4. Harrison, B.J., Symmons, D.P., Brennan, P., Barrett, E.M., and Silman, A.J. 1996. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 35:1096–1100.Google ScholarPubMed
5. Symmons, D., Turner, G., Webb, R., et al. 2002. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 41:793–800.CrossRefGoogle ScholarPubMed
6. Wolfe, F., and Cathey, M.A. 1991. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 18:1298–1306.Google ScholarPubMed
7. Wolfe, F., and Hawley, D.J. 1998. The long-term outcomes of rheumatoid arthritis: Work disability: a prospective 18-year study of 823 patients. J Rheumatol 25:2108–2117.Google Scholar
8. del Rincon, I.D., Williams, K., Stern, M.P., Freeman, G.L., and Escalante, A. 2001. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745.3.0.CO;2-#>CrossRefGoogle Scholar
9. Bacon, P.A., and Townend, J.N. 2001. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum 44:2707–2710.3.0.CO;2-M>CrossRefGoogle ScholarPubMed
10. van der Helm-van Mil, A. H., le Cessie, S., van Dongen, H., Breedveld, F.C., Toes, R.E., and Huizinga, T.W. 2007. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 56:433–440.Google ScholarPubMed
11. van der Helm-van Mil, A. H., Detert, J., Le, C. S., et al. 2008. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 58:2241–2247.CrossRefGoogle ScholarPubMed
12. Raza, K., Breese, M., Nightingale, P., et al. 2005. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 32:231–238.Google ScholarPubMed
13. Nell, V.P., Machold, K.P., Stamm, T.A., et al. 2005. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736.CrossRefGoogle ScholarPubMed
14. Quinn, M.A., Conaghan, P.G., O'Connor, P.J., et al. 2005. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:27–35.CrossRefGoogle ScholarPubMed
15. Goekoop-Ruiterman, Y.P., Vries-Bouwstra, J.K., Allaart, C.F.. et al. 2005. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381–3390.CrossRefGoogle ScholarPubMed
16. McInnes, I.B., and Schett, G. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429–442.CrossRefGoogle ScholarPubMed
17. Brentano, F., Kyburz, D., Schorr, O., Gay, R., and Gay, S. 2005. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol 233:90–96.CrossRefGoogle ScholarPubMed
18. Brennan, F.M., Hayes, A.L., Ciesielski, C.J., Green, P., Foxwell, B.M., and Feldmann, M. 2002. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheum 46:31–41.3.0.CO;2-5>CrossRefGoogle ScholarPubMed
19. Parsonage, G., Filer, A.D., Haworth, O., et al. 2005. A stromal address code defined by fibroblasts. Trends Immunol 26:150–156.CrossRefGoogle ScholarPubMed
20. Pilling, D., Akbar, A.N., Girdlestone, J., et al. 1999. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. Eur J Immunol 29:1041–1050.3.0.CO;2-#>CrossRefGoogle ScholarPubMed
21. Reparon-Schuijt, C. C., van Esch., W. J., van Kooten., C., et al. 2000. Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes. Arthritis Rheum 43:1115–1121.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
22. Bradfield, P.F., Amft, N., Vernon-Wilson, E., et al. 2003. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum 48:2472–2482.CrossRefGoogle Scholar
23. Buckley, C.D., Amft, N., Bradfield, P.F., et al. 2000. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 165:3423–3429.CrossRefGoogle ScholarPubMed
24. Muller-Ladner, U., Kriegsmann, J., Franklin, B.N., et al. 1996. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 149:1607–1615.Google ScholarPubMed
25. Taylor, P.C., and Sivakumar, B. 2005. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 17:293–298.CrossRefGoogle ScholarPubMed
26. Hyrich, K.L., Lunt, M., Dixon, W.G., Watson, K.D., and Symmons, D.P. 2008. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 47:1000–1005.CrossRefGoogle Scholar
27. Smolen, J.S., Beaulieu, A., Rubbert-Roth, A., et al. 2008. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997.CrossRefGoogle ScholarPubMed
28. Edwards, J.C., Szczepanski, L., Szechinski, J., et al. 2004. Efficacy of B-cell-targeted therapy with ritux-imab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581.Google Scholar
29. Genovese, M.C., Becker, J.C., Schiff, M., et al. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353: 1114–1123.CrossRefGoogle ScholarPubMed
30. Johnson, A.E., Gordon, C., Palmer, R.G., and Bacon, P.A. 1995. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 38:551–558.Google ScholarPubMed
31. Samanta, A., Roy, S., Feehally, J., and Symmons, D.P. 1992. The prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester city, UK. Br J Rheumatol 31:679–682.CrossRefGoogle ScholarPubMed
32. Gordon, C., and Salmon, M. 2001. Update on systemic lupus erythematosus: autoantibodies and apoptosis. Clin Med 1:10–14.CrossRefGoogle ScholarPubMed
33. Ho, A., Barr, S.G., Magder, L.S., and Petri, M. 2001. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 44:2350–2357.Google Scholar
34. Ho, A., Magder, L.S., Barr, S.G., and Petri, M. 2001. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 44:2342–2349.Google ScholarPubMed
35. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599–608.
36. Frostegard, J. 2008. Systemic lupus erythematosus and cardiovascular disease. Lupus 17:364–367.CrossRefGoogle ScholarPubMed
37. Bono, L., Cameron, J.S., and Hicks, J.A. 1999. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 92:211–218.CrossRefGoogle ScholarPubMed
38. Moroni, G., Pasquali, S., Quaglini, S., et al. 1999. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 34:530–539.CrossRefGoogle ScholarPubMed
39. Houssiau, F.A., Vasconcelos, C., D'Cruz, D., et al. 2004. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50:3934–3940.CrossRefGoogle Scholar
40. Fraenkel, L., MacKenzie, T., Joseph, L., Kashgarian, M., Hayslett, J.P., and Esdaile, J.M. 1994. Response to treatment as a predictor of long-term outcome in patients with lupus nephritis. J Rheumatol 21:2052–2057.Google Scholar
41. Esdaile, J.M., Joseph, L., MacKenzie, T., Kashgarian, M., and Hayslett, J.P.. 1994. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 21:2046–2051.Google ScholarPubMed
42. Moroni, G., Pasquali, S., Quaglini, S., et al. 1999. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 34:530–539.CrossRefGoogle ScholarPubMed
43. Weening, J.J., DAgati, V.D., Schwartz, M.M., et al. 2004. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530.CrossRefGoogle ScholarPubMed
44. Boumpas, D.T. 2004. Sequential therapies with intravenous cyclophosphamide and oral mycophenolate mofetil or azathioprine are efficacious and safe in proliferative lupus nephritis. Clin Exp Rheumatol 22:276–277.Google ScholarPubMed
45. Houssiau, F.A., Vasconcelos, C., D'Cruz, D., et al. 2002. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131.CrossRefGoogle Scholar
46. Walsh, M., James, M., Jayne, D., Tonelli, M., Manns, B.J., and Hemmelgarn, B.R. 2007. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2:968–975.CrossRefGoogle Scholar
47. Zhu, B., Chen, N., Lin, Y., et al. 2007. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22:1933–1942.CrossRefGoogle ScholarPubMed
48. Moore, R.A., and Derry, S. 2006. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 8:R182.CrossRefGoogle Scholar
49. Ginzler, E.M., Dooley, M.A., Aranow, C., et al. 2005. Mycophenolate mofetil or intravenous cyclophosph-amide for lupus nephritis. N Engl J Med 353:2219–2228.CrossRefGoogle ScholarPubMed
50. Houssiau, F.A., and Ginzler, E.M. 2008. Current treatment of lupus nephritis. Lupus 17:426–430.CrossRefGoogle ScholarPubMed
51. Gunnarsson, I., Sundelin, B., Jonsdottir, T., Jacobson, S.H., Henriksson, E.W., Van Vollenhoven, R.F. 2007. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56: 1263–1272.CrossRefGoogle ScholarPubMed
52. Vigna-Perez, M., Hernandez-Castro, B., Paredes-Saharopulos, O., et al. 2006. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83.CrossRefGoogle ScholarPubMed
D'Cruz, D.P., Khamashta, M.A., and Hughes, G.R. 2007. Systemic lupus erythematosus. Lancet 369:587–596.CrossRefGoogle ScholarPubMed
Klareskog, L., Catrina, A.I., and Paget, S. 2009. Rheumatoid arthritis. Lancet 373(9664):659–672.CrossRefGoogle ScholarPubMed
McInnes, I.B., and Schett, G. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429–442.CrossRefGoogle ScholarPubMed
Smolen, J.S., Aletaha, D., Koeller, M., Weisman, M.H., and Emery, P. 2007. New therapies for treatment of rheumatoid arthritis. Lancet 370(9602):1861–1874.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×